The Top Line
FDA Breakthrough Therapy and RMAT: Strategic Decisions That Can Accelerate Oncology Development (Sponsored)
June 16, 202620 min
Show notes
In this sponsored episode of The Top Line, host Stephanie Butler is joined by Sheila Plant, vice president of regulatory affairs at Allucent, to examine how FDA Breakthrough Therapy and RMAT designations can support more strategic oncology development. Although both pathways are intended to speed development, they are not interchangeable.
Transcript
Transcript not available for this episode yet.
More from The Top Line
GSK’s first lung cancer approval, a new IPO path and more
Jul 24, 202611 min
Why modern clinical trials need a finance-first strategy (Sponsored)
Jul 20, 202617 min
5 emerging biotech hubs
Jul 17, 202624 min
Decision readiness is the next AI advantage (Sponsored)
Jul 13, 202618 min
A $10B deal, China trial scrutiny and highlights from ADA 2026
Jul 10, 202624 min